<DOC>
	<DOCNO>NCT00934232</DOCNO>
	<brief_summary>Two main objective study : Primary : To determine MTD Busulfex ® give safely least number day myeloma patient either ≥65 year age ( Group 1 ) renal insufficiency ( Group 2 ) , define creatinine &gt; 3mg/dL creatinine clearance &lt; 30 mL/min . Secondary : To perform pharmacokinetic ( PK ) study evaluate individual variability relationship toxicity two group propose dose level .</brief_summary>
	<brief_title>Busulfan Multiple Myeloma</brief_title>
	<detailed_description>This study first line treatment multiple myeloma patient patient &gt; 65 year renal insufficiency Busulfan introduce cytopenia much slow melphalan time recover transplantation . The duration cytopenia busulfan therefore shorter . Busulfan give myeloma patient renal failure proven effective . The initial propose dose level study 3.2mg/kg body weight 6 hour 3 day . The next level 3.2mg/kg body weight 6 hour 4 day , 4.3 mg/kg body weight 6 hour 3 day , 5.6 mg/kg body weight 6 hour 2 day , 6.4 mg/kg body weight 6 hour 2 day . Three patient per group enter first level . Further enrollment dependent upon toxicity observe . All dose escalation initiate PI review toxicity data available prior dose level confirms safe proceed subsequent dose level ( ) . Maximum tolerate dose define dose level immediately dose level ≥ 2 6 patient experience grade 4 non-hematological toxicity unexpected , relate , serious , evaluate separately patient &gt; 65 year age patient renal insufficiency .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>1 . Subjects must ≥ 3 x 106 CD34 cell/kg storage study . 2 . Subjects must symptomatic multiple myeloma new patient consult HCI , opinion enrol physician , require treatment . 3 . Subjects must least 65 year age and/or diagnose renal insufficiency , define serum creatinine ≥3mg/dL creatinine clearance less 30mL/minute . 4 . Subjects must history chronic obstructive chronic restrictive pulmonary disease . Subjects must demonstrate adequate pulmonary function study define ≥50 % predict mechanical aspect ( FEV1 , FVC ) diffusion capacity ( DLCO ) . 5 . Subjects must demonstrate adequate cardiac function ( ≥40 % LVEF ECHO MUGA ) . 6 . Subjects must demonstrate adequate liver function total bilirubin transaminase level higher 1.5 time institutional upper limit normal . ( If total bilirubin &gt; 1.5 time upper limit normal , direct bilirubin need assess . Subject eligible long direct bilirubin &gt; 1.5 time upper limit normal ) 7 . Subjects must least one evaluable myeloma marker judge response : serum M protein &gt; 1g/dL , free light chain serum four time upper limit normal , urine M protein ≥ 500 mg , urine free light chain ≥ 500 mg/day , bone marrow plasmacytosis &gt; 20 % plasma cell , extramedullary plasmacytosis , MRI/FDGPET/CT scan demonstrate 1 focal lesion due myeloma . 8 . Subjects must SWOG performance score 02 unless due myelomarelated bone pain . 9 . Subjects must inform investigational nature study must sign IRBapproved informed consent accordance institutional federal guideline . 10 . Female participant childbearing potential must negative pregnancy test document within 10 day enrollment . 1 . Subjects must serum transaminase &gt; 1.5 time upper limit normal and/or direct bilirubin &gt; 1.5 time institutional upper limit normal ( direct bilirubin assess total bilirubin &gt; 1.5 time upper limit normal ) 2 . Subjects must HIV positive active Hepatitis B Hepatitis C infection . If serology antibody study positive , quantitative PCR must do confirm . 3 . Subjects must prior malignancy life expectancy , opinion investigator , likely determine prior malignancy myeloma . Patients must currently receive therapy prior malignancy . 4 . Subjects must prior autologous allogeneic bone marrow transplant . 5 . Subjects must pregnant nursing . Women men reproductive potential may participate unless agree use effective contraceptive method . 6 . Patients &lt; 3 million CD34 cells/kg store protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>cancer</keyword>
	<keyword>myeloma</keyword>
</DOC>